This post was originally published on this site
https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEG8C0KL_L.jpg
The deal provides Gilead access to Immunomedics’ breast cancer treatment drug, Trodelvy, which was granted an accelerated FDA approval in April.
Gilead said it would issue a tender offer to buy all the outstanding shares of Immunomedics for $88 per share in cash.
The offer will be funded through $15 billion in cash on hand, as well about $6 billion in newly issued debt, according to the statement.
The transaction is expected to close in the fourth quarter of 2020, the companies said.
